NRXP COVID-19 Vaccine Effectiveness Against Delta Variant

NASDAQ:NRXP   NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant.
Information was released by Israel Institute for Biological Research.

Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines.

I consider this a premium call, the upside i see here is 400%, or the 24usd resistance.

NRXP 52 Week Range 4.07 - 76.99usd. Now the price is 6.75usd.

Is this a buy or not?

Market Cap of only 396.97Mil


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.